Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PHARMACEUTICAL MANUFACTURING POLLUTANT CONTROL GUIDELINES

Executive Summary

PHARMACEUTICAL MANUFACTURING POLLUTANT CONTROL GUIDELINES will retain subcategories from the Environmental Protection Agency's 1983 final regulations based on Best Practicable Technology, EPA announced in a Dec. 16 Federal Register notice. The agency's final rule establishing "best conventional pollutant control technology" (BCT) effluent limitations guidelines denotes four subcategories for pollution control: fermentation; biological extraction; chemical synthesis; and formulation. In November 1982, EPA proposed to combine the four groups into one subcategory. After analysis of existing data, however, EPA says it agrees with objections to the 1982 proposal. The final regulation "would limit the discharge of five-day biochemical oxygen demand (BOD5) and total suspended solids (TSS) into waters of the U.S. by existing sources that conduct pharmaceutical manufacturing operations," EPA stated. The regulation also "maintains the acceptable pH range for pharmaceutical wastewater discharges." EPA said the regulation does not cover facilities which engage only in pharmaceutical research (chemical, biological or microbiological). EPA noted that BCT limitations are assessed "in light of a two-part 'cost reasonableness' test." The first test "compares the cost for private industry to reduce its conventional pollutants to the costs for similar levels of reduction at publicly owned treatment works" and the second "examines the cost effectiveness of additional treatment beyond BPT" (Best Practicable Technology). EPA said it originally proposed BCT effluent limitation guidelines more stringent than the BPT effluent limitation guidelines. However, EPA stated, "none of the BCT candidate technologies pass the recently promulgated BCT cost test in any of the subcategories. Thus, final BCT effluent limitation guidelines are being established equal to existing BPT effluent limitation guidelines for all four subcategories." The agency also noted that it has made changes to its pharmaceutical treatment plant costing methodology since the 1982 proposal. EPA referred to the New Source Performance Standards (NSPS) model plant costs in which the agency "used subcategory average data, i.e. flow, influent and effluent BOD5 and TSS concentrations." BPT and BCT individual plant cost methodology differs from NSPS methodology only in that EPA used data supplied by individual plants when available and subcategory average data when individual plant data were not available.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011229

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel